We are live on ! Find out more
ANIP icon

ANI Pharmaceuticals

132 hedge funds and large institutions have $413M invested in ANI Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 50 increasing their positions, 30 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

84% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 19

73% more capital invested

Capital invested by funds: $239M → $413M (+$174M)

67% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 30

13% more funds holding

Funds holding: 117132 (+15)

3.5% less ownership

Funds ownership: 57.11%53.6% (-3.5%)

36% less call options, than puts

Call options by funds: $2.3M | Put options by funds: $3.57M

Holders
132
Holders Change
+15
Holders Change %
+12.82%
% of All Funds
2.03%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
35
Increased
50
Reduced
30
Closed
19
Calls
$2.3M
Puts
$3.57M
Net Calls
-$1.27M
Net Calls Change
-$818K
Name Holding Trade Value Shares
Change
Change in
Stake
GC
51
Globeflex Capital
California
$1.01M
New York State Teachers Retirement System (NYSTRS)
52
New York State Teachers Retirement System (NYSTRS)
New York
$999K -$4.3K -100 -0.5%
CAM
53
ClariVest Asset Management
California
$995K +$926K +21,553 +50,123%
Wells Fargo
54
Wells Fargo
California
$907K +$97.3K +2,264 +13%
DC
55
Defender Capital
North Carolina
$876K
Prudential Financial
56
Prudential Financial
New Jersey
$737K -$450K -10,471 -40%
MUAMU
57
Mitsubishi UFJ Asset Management (UK)
United Kingdom
$737K
FDCDDQ
58
Federation des caisses Desjardins du Quebec
Quebec, Canada
$737K +$466K +10,849 +211%
Barclays
59
Barclays
United Kingdom
$736K +$352K +8,190 +105%
California State Teachers Retirement System (CalSTRS)
60
California State Teachers Retirement System (CalSTRS)
California
$718K +$90.1K +2,097 +16%
CS
61
Credit Suisse
Switzerland
$688K -$543K -12,646 -46%
AllianceBernstein
62
AllianceBernstein
Tennessee
$668K -$134K -3,117 -18%
Brown Advisory
63
Brown Advisory
Maryland
$659K
MFIM
64
Mesirow Financial Investment Management
Illinois
$566K
SG Americas Securities
65
SG Americas Securities
New York
$547K -$32.2K -749 -6%
Commonwealth Equity Services
66
Commonwealth Equity Services
Massachusetts
$528K +$493K +11,478 New
PCM
67
Perkins Capital Management
Minnesota
$503K -$135K -3,150 -22%
TI
68
Trexquant Investment
Connecticut
$470K +$438K +10,199 New
Bank of America
69
Bank of America
North Carolina
$448K -$205K -4,768 -33%
MAM
70
Martingale Asset Management
Massachusetts
$439K +$409K +9,508 New
Jane Street
71
Jane Street
New York
$434K +$405K +9,414 New
Canada Life
72
Canada Life
Manitoba, Canada
$423K +$43.7K +1,017 +12%
YCM
73
Yousif Capital Management
Michigan
$422K +$394K +9,161 New
Thrivent Financial for Lutherans
74
Thrivent Financial for Lutherans
Minnesota
$406K +$41.9K +974 +12%
Citigroup
75
Citigroup
New York
$398K +$115K +2,673 +45%

ANIP Hedge Fund Activity: Q4 2021 in Review

132 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q4 2021, worth a combined $413M — up 73% from $239M a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new ANIP positions and 19 closed out — a net gain of 16 holders — while 50 added to existing stakes and 30 trimmed.

The largest buyer was Rubric Capital Management (New York), opening a new position worth an estimated $13.2M. The largest seller was Goldman Sachs, cutting an estimated $11.7M.

  • 132 institutional investors held ANI Pharmaceuticals (ANIP) as of Q4 2021, up from 117 in Q3 2021.
  • Funds reported $413M of ANI Pharmaceuticals stock for Q4 2021, up 73% quarter-over-quarter.
  • 35 funds opened new ANI Pharmaceuticals positions in Q4 2021 and 19 closed out, a net change of +16 holders.
  • The largest ANI Pharmaceuticals buyer in Q4 2021 was Rubric Capital Management (New York), an estimated $13.2M added.
  • The largest ANI Pharmaceuticals seller in Q4 2021 was Goldman Sachs, an estimated $11.7M sold.

Based on aggregated 13F filings for Q4 2021.